Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions

Bache, Bache Emmanuel; Grobusch, Martin P.; Agnandji, Selidji Todagbe

dc.contributor.author	Grobusch, Martin
dc.contributor.author	Agnandji, Selidji Todagbe
dc.date.accessioned	2020-10-28T13:42:34Z
dc.date.available	2020-10-28T13:42:34Z
dc.date.issued	2020
dc.identifier.issn	1746-0921
dc.identifier.uri	http://hdl.handle.net/10900/108781
dc.language.iso	en	de_DE
dc.publisher	Future Medicine Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.2217/fmb-2019-0237	de_DE
dc.subject.ddc	570	de_DE
dc.subject.ddc	610	de_DE
dc.title	Safety, immunogenicity and risk-benefit analysis of rVSV-ΔG-ZEBOV-GP (V920) Ebola vaccine in Phase I-III clinical trials across regions	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_02105
utue.publikation.seiten	85-106	de_DE
utue.personen.roh	Bache, Bache Emmanuel
utue.personen.roh	Grobusch, Martin P.
utue.personen.roh	Agnandji, Selidji Todagbe
dcterms.isPartOf.ZSTitelID	Future Microbiology	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	15	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE